Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Atara Biotherapeutics is a biotechnology business based in the US. Atara Biotherapeutics shares (ATRA) are listed on the NASDAQ and all prices are listed in US Dollars. Atara Biotherapeutics employs 340 staff and has a trailing 12-month revenue of around $70.9 million.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $4.94 |
|---|---|
| 52-week range | $2.83 - $16.07 |
| 50-day moving average | $3.98 |
| 200-day moving average | $4.84 |
| Wall St. target price | $18.88 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.65 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.94 from 2023-01-26
| 1 week (2023-01-20) | 26.99% |
|---|---|
| 1 month (2022-12-28) | 65.22% |
| 3 months (2022-10-28) | 2.28% |
| 6 months (2022-07-28) | 55.35% |
| 1 year (2022-01-28) | -66.76% |
|---|---|
| 2 years (2021-01-28) | -74.00% |
| 3 years (2020-01-28) | 14 |
| 5 years (2018-01-26) | 37.25 |
| Revenue TTM | $70.9 million |
|---|---|
| Gross profit TTM | $-229,598,000 |
| Return on assets TTM | -45.58% |
| Return on equity TTM | -99.38% |
| Profit margin | 0% |
| Book value | $1.97 |
| Market capitalisation | $451.1 million |
TTM: trailing 12 months
We're not expecting Atara Biotherapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Atara Biotherapeutics's shares have ranged in value from as little as $2.83 up to $16.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Atara Biotherapeutics's is 0.7677. This would suggest that Atara Biotherapeutics's shares are less volatile than average (for this exchange).
Atara Biotherapeutics, Inc. , an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
